Subscribe
formatoriginal-biogen
Formatoriginal / Shutterstock.com
2 December 2021Americas

Fed Circuit split decision denies Biogen’s bid to revive MS drug patent

The US Court of Appeals for the Federal Circuit has refused Biogen’s attempt to revive a key patent for its multiple sclerosis drug Tecfidera (dimethyl fumarate), leaving Mylan’s successful challenge intact.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Mylan launches Tecfidera generic amid Biogen battle
20 August 2020   Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Americas
Groups urge Fed Circ to rehear Biogen patent case
18 January 2022   Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Mylan launches Tecfidera generic amid Biogen battle
20 August 2020   Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Americas
Groups urge Fed Circ to rehear Biogen patent case
18 January 2022   Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

More on this story

Americas
Mylan launches Tecfidera generic amid Biogen battle
20 August 2020   Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19.
Americas
Biogen sues Teva over MS generic
18 March 2021   A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.
Americas
Groups urge Fed Circ to rehear Biogen patent case
18 January 2022   Pharma, biotech and chemical industry groups have asked the US Court of Appeals for the Federal Circuit to review its decision to invalidate a Biogen patent for lacking written description.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?